ACC CardiaCast

This episode is part of ACC's ongoing initiative on Implementing the 2026 Dyslipidemia Guidelines . Join Drs. Pam Morris and Roger Blumenthal as they explore updates to the Dyslipidemia Guidelines, the patient populations who benefit most, and how to make sense of all of this new information. They provide a practical, evidence‑based discussion designed to support better decision‑making in everyday care. This podcast is part of the ACC's Implementing the 2026 Dyslipidemia Guidelines: From Risk Stratification to Personalized Treatment online course, supported by Merck & Co. and Eli Lilly and Company. Visit the online course to access additional educational activities on this topic.

This episode is part of ACC's ongoing initiative to review aortic stenosis care and its approach to screening and diagnosis. Drs. Wayne Batchelor and Sammy Elmariah review the barriers to aortic stenosis diagnosis. The conversation highlights symptom variability, sex-based and demographic differences, and screening gaps in the real-world practice. This podcast is part of the ACC's Transforming Aortic Stenosis Care: An Optimal Approach to Screening & Diagnosis initiative, supported by an educational grant from Edwards Lifesciences.

This episode is part of ACC's ongoing initiative on i mplementing the 2026 Dyslipidemia g uidelines. Join Drs. Samuel Kim and Romit Bhattacharya as they review new therapeutic developments from the guidelines during this discussion on the intersections of d yslipidemia and c ardiometabolic s yndrome m anagement . This podcast is part of the ACC's Implementing the 2 026 Dyslipidemia Guidelines: From Risk Stratification to Personalized Treatment initiative, supported by Merck & Co , and Eli Lilly and Company .

This episode is part of ACC's ongoing initiative to recognize the risks and tackle management of h ypertriglyceridemia (HTG) and s evere h ypertriglyceridemia ( sHTG ) . Drs. Michael Miller and Archna Bajaj discuss the importance of correctly diagnosing sHTG , recognizing f amilial c hylomicronemia s yndrome ( FCS ) , and following guideline‑based testing sequences. This podcast is part of the ACC's Hypertriglyceridemia and Cardiovascular Health: Recognizing Risks and Tackling Management initiative, supported by Ionis Pharmaceuticals.

In this CardiaCast episode, Kevin M. Alexander, MD is joined by Sarah Cuddy, MBBCh, to discuss the latest clinical data for investigational therapies and available treatments for transthyretin amyloid cardiomyopathy (ATTR-CM), as well as the potential implications of these findings on clinical practice and future clinical studies. First, they will explore results from CARDIO-TTRansform, the phase 3 trial of eplontersen in ATTR-CM, followed by the results from REVEAL, the phase 3 trial using radiotracer I-124 evuzamitide to detect cardiac amyloidosis. Next, they will discuss findings from ATTRibute-CM and its open-label extension on the survival benefits of acoramidis in variant ATTR-CM (ATTRv-CM) over 54 months. Lastly, they will cover recently published studies describing the extracardiac effects of available therapies for ATTR-CM, specifically those describing the effects of acoramidis on kidney function and the effects of vutrisiran on gastrointestinal events. This activity is supported by an educational grant from BridgeBio and developed by Med-IQ in collaboration with the American College of Cardiology .

This episode of CardiaCast will feature a discussion on risk assessment and genetics in the prevention of cardiovascular disease. This podcast is supported by Esperion, Merck, and Novartis .

This episode of CardiaCast will feature a discussion on risk assessment and the treatment of hypertriglyceridemia. This podcast is supported by Esperion, Merck, and Novartis .

In this final episode of the Increasing Role of UACR in Cardiovascular Care series, Drs. Ankeet Bhatt and Brendan Neuen will break down why UACR screening is one of the most powerful yet underused tools for identifying early cardiovascular risk. Together, they examine the latest evidence on therapies and lifestyle strategies that reduce albuminuria, discuss their impact on kidney and cardiovascular risk, and highlight practical considerations for integrating these approaches into everyday clinical care. This podcast is supported by a grant from Boehringer Ingelheim . V isit the course page to learn more about the r ole of UACR in Cardiovascular Care .

The second episode of t he Increasing Role of UACR in Cardiovascular Care series focuses on the most recent evidence-based guidelines for elevated UACR and related cardiovascular ( CV ) conditions. Dr. Ankeet Bhatt interviews Dr. Nihar Desai on key terminology for albuminuria and discuss CV conditions associated with UACR as a biomarker . This podcast is supported by a grant from Boehringer Ingelheim . V isit the course page to learn more about the r ole of UACR in Cardiovascular Care .

This episode of CardiaCast will feature a discussion on the treatment of a therosclerotic cardiovascular disease ( ASCVD ) risk – from lifestyle to advanced therapies , led by Dr. Maya Safarova . The conversation covers lifestyle "therapy ", the treatment algorithm for primary and secondary prevention, and what's on the horizon for ASCVD. This podcast is supported by Esperion, Merck, and Novartis .

In this first episode of The Increasing Role of U rine A lbumin- C reatinine R atio (UACR) in Cardiovascular Care series, Dr. Ankeet Bhatt interviews Dr. Katherine Tuttle on UACR, its role in kidney disease, and the importance of screening. Listen to Dr. Tuttle provide an overview of the most recent evidence-based practices for UACR screening in cardiovascular disease risk assessment. T his podcast is supported by a grant from Boehringer Ingelheim . Visit the course page to learn more about the role of UACR in cardiovascular care.

This episode is part of ACC's ongoing initiative to recognize the risks and tackle management of Hypertriglyceridemia (HTG) and Severe Hypertriglyceridemia ( sHTG ) . Drs. Michael Miller and Monica Aggarwal review and emphasize the need to understand the multifactorial and genetic causes of HTG and sHTG , as well as the associated risks of pancreatitis and ASCVD. This podcast is part of the ACC's Hypertriglyceridemia and Cardiovascular Health: Recognizing Risks and Tackling Management initiative, supported by Ionis Pharmaceuticals.

This episode is part of ACC's ongoing educational initiative to enhance the recognition, diagnosis, and management of paroxysmal supraventricular tachycardia (PSVT). Faculty review contemporary acute treatment approaches, including established therapies, recent advances, and first-line emergency department strategies with attention to efficacy and safety. The discussion also addresses management of refractory or recurrent cases, decision-making across diverse patient populations and care settings, and criteria for hospital admission versus discharge. Additionally, it provides practical guidance on patient education, symptom recognition, and selecting treatments that balance effectiveness, safety, convenience, and patient confidence. This podcast is part of the ACC's educational initiative on PSVT, supported by an independent educational grant from Milestone Pharmaceuticals Inc. Click here to learn more.

This episode provides a team-based overview of diagnosing and managing acute paroxysmal supraventricular tachycardia (PSVT) across care settings. It emphasizes how patients interact with providers from primary care to electrophysiology and the importance of coordinated roles. The discussion highlights shared decision-making and targeted education to help patients recognize symptoms, understand recurrence risk, and respond to episodes. Key topics include when to seek care, initial self-management steps, and long-term options such as medication, ablation, or observation. It also reviews practical action plans and the role of newer therapies like intranasal etripamil in individualized care. This podcast is part of the ACC's educational initiative on PSVT, supported by an independent educational grant from Milestone Pharmaceuticals Inc. Click here to learn more: https://learn.acc.org/Page/LearnSVT

This episode is part of ACC's ongoing initiative to advance education on remote hemodynamic monitoring in heart failure management. Drs. Vishal Rao and Sandip Zalawadiya, along with Ms. Lisa Rathman, CRNP, discuss patient cases highlighting both successful pulmonary artery (PA) pressure device implantation and associated complications. They emphasize key practical considerations, including device placement, patient selection, waveform accuracy, troubleshooting, and team coordination during the procedure. This podcast is part of the ACC's Pulmonary Artery Pressure Monitoring: Transforming HF Patient Care initiative, supported by Abbott.

This episode is part of ACC's ongoing effort to improve recognition and diagnosis of arrhythmias in clinical practice. In this CardiaCast , faculty explore a modern approach to identifying paroxysmal supraventricular tachycardia (PSVT), with a focus on real-world diagnostic challenges. The discussion highlights how to differentiate PSVT from other common causes of palpitations, interpret normal electrocardiograms between episodes, and recognize patterns that may be misattributed to anxiety , particularly in otherwise healthy patients. The episode also reviews practical strategies for rhythm capture, including ambulatory monitoring and patient-directed documentation, to support timely and accurate diagnosis. This podcast is part of the ACC's educational initiative on PSVT, supported by an independent educational grant from Milestone Pharmaceuticals Inc. Click here to learn more: https://learn.acc.org/Page/LearnSVT

In this episode, hosts Rosy Thachil, MD, FACC, and Shashank Sinha, MD, FACC, are joined by Jacob Jentzer, MD, FACC, and Ami Bhatt, MD, FACC, Chief Innovation Officer of the American College of Cardiology, for an engaging discussion on AI in the CICU: Transforming Cardiac Critical Care. The conversation explores how artificial intelligence (AI) is beginning to reshape cardiac critical care—from improving clinical decision support and hemodynamic monitoring to predict patient deterioration and optimizing CICU workflows. The panel also discusses the opportunities and challenges of integrating AI into everyday practice and what the future may hold for clinicians caring for the sickest cardiovascular patients.

This CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC . 26, with a focused review of newly released late-stage clinical trial data for currently available disease-modifying therapies. Expert faculty Drs. Sarah Cuddy and Prem Soman break down how emerging evidence is reshaping treatment selection, including considerations for efficacy, safety, and patient-specific factors. The discussion highlights practical strategies for integrating these new findings into real-world clinical practice to optimize outcomes for patients with ATTR-CM. This podcast is developed by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Bridge Bio.

In this episode of CardiaCast , Dr. Michael Blaha will be joined by Dr. Ann Marie Navar to discuss the 2026 updates to ACC/AHA guideline on management of dyslipidemia and key clinical trial data supporting the use of PCSK9 inhibitors in getting patients to their lipid goals. They discuss available PCSK9 inhibitors, including the recently approved injectable PCSK9 inhibitor lerodalcibep-liga . After discussing the limitations and barriers associated with injectable PCSK9 inhibitors, they will introduce the emerging oral PCSK9 inhibitors and explore the latest clinical data for enlicitide and AZD0780 . This podcast was developed by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Merck.

This episode is part of ACC's ongoing initiative to advanc e education on remote hemodynamic monitoring in heart failure management. Drs. Michael Zile, JoAnn Lindenfeld, and William Abraham explore the core capabilities of these devices and how emerging innovations aim to address current limitations. The conversation highlights how clinicians can interpret pressure data and define optimal targets, incorporates the growing role of direct-to-patient communication, and concludes with practical strategies for integrating device-generated insights into clinical workflows to improve patient outcomes. This podcast is part of the ACC's Pulmonary Artery Pressure Monitoring: Transforming HF Patient Care initiative, supported by Abbott .